Jefferies Reiterates Bullish View on MannKind (MNKD) Following Positive Physician Feedback From ADA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on tech boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil prices rise on Trump timeline for Iran peace deal: after US elections
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sanofi (SNY) 'Seemingly Committed' to MannKind's (MNKD) Afrezza, RBC Says; 2nd-Half Efforts to Focus on Awareness
June 9, 2015 12:04 PM EDTRBC Capital analyst Adnan Butt weighed in on MannKind (NASDAQ: MNKD) after partner Sanofi's (NYSE: SNY) update at ADA included Afrezza where it highlighted selling efforts will pick up in second-half. While discussion was modest, SNY plans a more direct patient focus in second half, the analyst comments.
Butt said while while they would have appreciated greater focus, given investments and plans for second half, SNY appears committed to Afrezza for now. He said what matters still is: 1) the growth trajectory in prescriptions 2) hurdles getting worked out, 3) whether... More
MannKind (MNKD) Gains Amid Ongoing Talk of Short Squeeze
June 8, 2015 9:51 AM EDTMannKind (NASDAQ: MNKD) advanced over 5% Monday, extending recent gains amid ongoing talk of a squeeze in the heavily shorted name.
113 million shares of the stock were held short as of May 15, or about 42% of the float. Days to cover was 14.5 on average volume of 7.8 million.
... More